Latest News

Newsletter 1 December 2017

Extraordinary General Meeting and new directed share issue to take Rabeximod through Phase 2B trials Prior to the extraordinary general meeting (EGM) that will be held in Malmö on December 11, at 10AM, I would first like to thank shareholders for their considerable interest in participating in the EGM. As you may already know, we […]

Read More

Newsletter November 2017

CEO comments I am currently putting the finishing touches to the list of meetings we have booked with companies at Bio Europe in Berlin, which is being held from Monday to Wednesday this week. Bio Europe is a major event during which small companies with new technologies and substances under development meet drug companies that […]

Read More

Newsletter August 2017

CEO comments I hope that you all have had a chance to enjoy some sunshine and warm days in July. Cyxone, in collaboration with our partners, has been working even during the month of July to ensure that the studies with T20K will go as planned, and to prepare financing for the Phase IIB studies […]

Read More

Newsletter July 2017

CEO’s comments Positive comments and questions about Cyxone, T20K and Rabeximod continue to flood in. I am grateful for all the interest, and felt that in this newsletter I would try to offer a little more background so that you could better grasp our reasoning. New safety data for T20K Development work on T20K is […]

Read More

Newsletter June 2017

CEO’s comments We have received many positive reactions and relevant questions since we announced our plans to acquire Phase II substance Rabeximod from OxyPharma. Naturally, a brief media release cannot provide comprehensive information about all the various aspects related to such an acquisition, so we will be looking to provide Cyxone shareholders with information in […]

Read More